The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 25, 2025
Filed:
Sep. 08, 2023
Institut National DE LA Santé ET DE LA Recherche Médicale, Paris, FR;
Universite Paris Cite, Paris, FR;
Fondation Imagine, Paris, FR;
Assistance Publique-hôpitaux DE Paris (Aphp), Paris, FR;
Universidad DE Granada, Granada, ES;
Laurence Legeai-Mallet, Paris, FR;
Antonio Segura Carretero, Granada, ES;
Maria De La Luz Cadiz Gurrea, Granada, ES;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris, FR;
FONDATION IMAGINE, Paris, FR;
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), Paris, FR;
UNIVERSIDAD DE GRANADA, Granada, ES;
Abstract
FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (−)-epicatechin fromand showed that (−)-epicatechin treatment significantly increases the length of the Fgfr3femurs comparing to Fgfr3femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (−)-epicatechin for the treatment of FGFR3-related chondrodysplasias.